Casi Pharmaceuticals, INC

CASI Pharmaceuticals, Inc. announced that ETP Global III Fund LP has purchased a $5 million convertible note, the fourth tranche of a $20 million financing, with conversion rights into ordinary shares.

CASI Pharmaceuticals, Inc. announced ETP Global III Fund L.P. purchased a $5 million convertible note, marking the third tranche of a $20 million financing.

CASI Pharmaceuticals, Inc. has secured a $5 million convertible promissory note from ETP Global III Fund LP to fund clinical trials in China and general operations.

CASI Pharmaceuticals, Inc. has secured a $5 million convertible promissory note from ETP Global III Fund LP, marking the first tranche of a $20 million financing initiative.

IDG-Accel China Growth Fund III and related entities have reported a decrease in their beneficial ownership of CASI Pharmaceuticals, Inc. ordinary shares to below 5% due to an increase in the total outstanding shares.

A group of investors, including Sparkle Byte Ltd. and individuals, updated their beneficial ownership in CASI Pharmaceuticals, Inc. to 5% due to an increase in the company's total outstanding shares.

Foresite Capital reports a complete divestment of its beneficial ownership in CASI Pharmaceuticals, Inc., holding 0% of ordinary shares as of December 31, 2025.

Chen Zhenfeng has reported a beneficial ownership of 11.0% in CASI Pharmaceuticals, Inc., totaling 2,255,636 ordinary shares.

Foresite Capital Fund VI LP, Foresite Capital Management VI LLC, and James Tananbaum collectively report a 6.3% beneficial ownership in CASI Pharmaceuticals, Inc. Ordinary Shares.

Foresite Capital entities and James Tananbaum report beneficial ownership of 5.1% of CASI Pharmaceuticals, Inc.'s Ordinary Shares.

Panacea Venture Healthcare Fund II, L.P. and its related entities, including James Huang, reported continued beneficial ownership of 13.8% of CASI Pharmaceuticals, Inc.'s Ordinary Shares.